Pathway for this topic Myeloma Non-Hodgkin’s lymphoma Blood conditions. Magnesium levels of patients on dialysis are typically higher than of those with normal renal function; use of magnesium salts may place a patient at risk for hypermagnesemia and respiratory arrest. Data sources include IBM Watson Micromedex (updated 7 Dec 2020), Cerner Multum™ (updated 4 Dec 2020), ASHP (updated 3 Dec … An advantage for calcium acetate is less systemic absorption compared to other calcium salts, but it still can cause hypercalcemia. Med Lett Drugs Ther. Lexi-Comp Online. Calcium acetate is fairly well tolerated but can be associated with hypercalcemia, nausea, and vomiting.2, Calcium-based phosphate binders are the mainstay of phosphate-lowering therapy in CKD stage 4.3,4 In stage 5, there is a greater increase in phosphate, and concomitant use of calcium-based phosphate binders leads to an increase in serum calcium and phosphate. In: Chisholm-Burns MA, Wells BG, Schwinghammer TL, et al, eds. 2013 May;73(7):673-88. In chronic hypophosphatemia, standard treatment includes oral phosphate supplementation and active vitamin D. Future treatment for specific disorders associated with chronic hypophosphatemia may include cinacalcet, calcitonin, or dypyrimadole. Aluminum Hydroxide: The antacid aluminum hydroxide (various formulations) is a phosphate binder used to treat hyperphosphatemia. 2015;66(3):478-488.19. The recently approved iron-based products may have a role in certain patients, but the long-term safety risk of these products has not been established. Hyperphosphatemia Treatment Hyperphosphatemia has two types of treatment. Phosphate binders such as aluminum-based antacids, magnesium-based antacids, calcium carbonate, calcium acetate, sevelamer, and lanthanum may be necessary for those patients whose phosphorus levels stay elevated despite dietary restrictions. Am J Kidney Dis. Floege J, Covic AC, Ketteler M, et al. Velphoro (sucroferric oxyhydroxide) package insert. The four parathyroid glands normally are located behind the four poles of the thyroid gland. 1. In patients with normal kidney function, the treatment should be focused on promoting phosphaturia with the administration of normal saline as well as acetazolamide and sodium bicarbonate if needed. You can treat hyperphosphatemia via diet (which we will get into later), but it can also be treated via some medical options. dialysis treatment and the use of drugs that include phos- phate binders, active/analog vitamin D, and calcimimet- ics.3,11Renal replacement therapy with dialysis is needed to compensate for loss of kidney function in advanced Most patients are asymptomatic and the symptoms, when present, are usually related to other abnormalities that may be associated (in hypocalcemic patients: muscle cramps, tetany, numbness and tingling; in uremic patients, fatigue, shortness of breath, nausea, sleep disorders). Re-start treatment at the first reduced dose level. Magnesium Hydroxide: The antacid/laxative magnesium hydroxide (various formulations) is available as tablets or oral suspension. Chronic hyperphosphatemia, which occurs often in patients with chronic kidney disease, should be treated with low phosphate diet to a maximum dietary intake of 900mg/day (avoid dairy products, sodas, processed foods) and phosphate binders (e.g. Kidney Int. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Hyperphosphatemia is when you have too much phosphate in your blood. Adverse effects and toxicity limited the use of these agents, and therapy evolved with calcium carbonate, calcium acetate, sevelamer, and lanthanum carbonate. This has not been reported in iron-based phosphate binders, but it remains a consideration.13, Sucroferric Oxyhydroxide: The first iron-based phosphate binder, sucroferric oxyhydroxide (Velphoro), was approved in 2013.15 This product is indicated for the treatment of hyperphosphatemia in patients with CKD on dialysis. Joy MS, Finn WF. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Hyperlipidemia. The mainstay of treatment in patients with advanced chronic kidney disease is reduction of phosphate intake, which is usually accomplished with avoidance of foods containing high amounts of phosphate and with use of phosphate-binding drugs taken with meals. 2013;7(6):322-342.12. Acute hyperphosphatemia is often a result of intracellular -> extracellular shift (tumor lysis syndrome, rhabdomyolisis, among other causes). The active form of the drug is insoluble and cannot be metabolized or absorbed. 2014;86(3):638-647.15. Upward dose titration may be required to keep the phosphate level <6 mg/dL. Swainston Harrison T, Scott L. Lanthanum carbonate. P Range: Reccomendation < 3.5: assess diet, decrease dose or stop binder >5.5: Most people have no symptoms while others develop calcium deposits in the soft tissue. Patients with acute hyperphosphatemia and bad kidney function may benefit from insulin and glucose or dialysis (peritoneal dialysis may be better in such cases). 3rd ed. Based on these findings, Am J Kidney Dis. Medscape. 16 no. To comment on this article, contact rdavidson@uspharmacist.com. Cambridge, MA: Genzyme Corporation; 2015.23. 2006;48(1228):15-16.8. Sevelamer is an insoluble polymer that is not absorbed from the gastrointestinal (GI) tract and is considered as effective as calcium acetate or calcium carbonate in phosphorus-lowering ability.10 Sevelamer has been shown to decrease cardiovascular mortality in CKD patients.11 It can decrease absorption of various medications such as vitamins D, E, K, folic acid, levothyroxine, mycophenolate, tacrolimus, and quinolone antibiotics. Control of Hyperphosphatemia among Patients with ESRD. Salusky IB, Foley J, Nelson P, Goodman WG. Overall cost of this medication is low, so it is an attractive first-line agent if hypercalcemia is not a concern.8, Calcium Acetate: Approved in 1990, calcium acetate (PhosLo, various other brands) is considered a first-line therapy for lowering phosphate in CKD stage 4. Medications causing hyperphosphatemia include phosphorus-containing laxatives, oral phosphorus supplements, vitamin D supplements, and the bisphosphonates.1,2, It is essential for the pharmacist to recognize that in the setting of advanced chronic kidney disease (CKD), dialysis does not remove all phosphorus as it does other electrolytes, and many patients will require a phosphate binder. Hyperphosphatemia is a serum phosphate concentration of more than 4.5 mg / dL (greater than 1.46 mmol / L). Abstract; Joy MS, Finn WF. It has been used for decades in patients with high serum phosphate who are undergoing dialysis and is one of the most commonly used phosphate binders in practice.2 The usefulness of calcium carbonate as a phosphate binder is limited by its insolubility at high gastric pH, which is common in those with renal disease.7 The greatest safety concern is hypercalcemia, which has the potential to cause arterial calcification and has been associated with cardiac death. Sucroferric oxyhydroxide has been studied in clinical trials for up to 52 weeks.16, Ferric Citrate: Ferric citrate (Auryxia) is an oral iron-based phosphate binder that was approved by the FDA in 2014 for management of hyperphosphatemia in patients with CKD on dialysis.17 Upon ingestion, this product dissociates into its ferric iron and citrate components. The treatment of acute hyperphosphatemia includes volume expansion, dialysis, and administration of phosphate binders. Society guideline links: Fluid and electrolyte disorders in adults Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors Overview of the causes and treatment of hyperphosphatemia Fifty percent of mortality in patients with CKD is related to cardiovascular complications, with the highest risk being in the presence of hyperphosphatemia, hypercalcemia, and hyperparathyroidism.3 In general, the goal is to achieve a phosphorus concentration of 2.7 to 4.6 mg/dL in patients not receiving dialysis. Perform parathyroidectomy in patients with renal failure who have tertiary (autonomous) hyperparathyroidism complicated by hypercalcemia, hyperphosphatemia, and severe bone disease. In: Chisholm-Burns MA, Wells BG, Schwinghammer TL, et al, eds. Moderate Hypophosphataemia (0.3-0.59mmol/L): Phosphate Sandoz® 1-2 tablets orally three times daily (each tablet contains 16mmol phosphate, 3mmol potassium and 20mmol sodium). Sucroferric oxyhydroxide has not been studied in patients who had conditions where iron accumulation is common or who had GI disorders. Renvela (sevelamer carbonate) package insert. Phoslyra (calcium acetate oral solution) package insert. TABLE 2 summarizes the place in therapy, dosing, adverse-effect profile, and patient considerations for these agents. The major strategies for treating hyperphosphatemia are as follows: 1. Published by Elsevier Inc. Ther Adv Cardiovasc Dis. The tablets should not be swallowed but can be chewed or crushed.15, The most common adverse effects of sucroferric oxyhydroxide in clinical trials were diarrhea, discolored feces (black), nausea, and abnormal taste.14-16 Sucroferric oxyhydroxide may affect absorption of some medications; alendronate and doxycycline should be separated by at least one hour and concurrent use of levothyroxine and vitamin D should be avoided entirely. Sucroferric oxyhydroxide is an iron(III) oxyhydroxide molecule bound to a carbohydrate molecule, with iron constituting approximately 20% of the molecular weight. however can lead to inadequate treatment, so guidelines have been developed to assure patients, caregivers, and financial providers that reversal of the uremic state is the best that can be offered ... controls hyperphosphatemia, reduces hypertension, and results in regression of left ventricular hypertrophy5,6. Malesker MA, Morrow LE. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Causes of false elevations of measured phosphate (pseudohyperphosphatemia): Blood sample taken from line containing heparin or alteplase As we have mentioned, a significant element of treating hyperphosphatemia is treating the underlying cause of the condition. The glands secrete parathyroid hormone (PTH), which is the primary regulator of calcium homeostasis.4 The glands tightly regulate the extracellular calcium concentration within a narrow normal range. Patients should be monitored regularly for iron overload. Lexi-Drugs. The pharmacist should be able to recognize when oral phosphate binders are needed and be familiar with the risks and benefits of available treatments. This guideline should be used to treat hyperphosphataemia and secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) (all stages including those requiring dialysis). Hyperphosphatemia and phosphate binders. more common: symptomatic hypocalcemia Phosphate binds calcium, … Anaphylaxis: assessment and referral after emergency treatment Blood and bone marrow cancers. Sucroferric oxyhydroxide and ferric citrate are calcium-free and may offer benefits in those with a high pill burden and in patients with concurrent anemia, respectively. Severe hypomagnesemia Oral phosphate binders in CKD—is calcium the (only) answer? This product is no longer considered a first-line agent, as long-term use is associated with constipation, aluminum toxicity, osteomalacia, and encephalopathy.5 Aluminum antacids may also decrease the absorption of many other medications such as fluoroquinolones, tetracyclines, and thyroid hormones. PhosLo (calcium acetate) gelcaps package insert. For patients with CKD refractory hyperphosphatemia despite diet and binders, daily or prolonged dialysis, calcimimetics or parathyroidectomy may be necessary. The target phosphorus concentration for dialysis patients is 3.5 to 5.5 mg/dL.3, The Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines categorize CKD by stages (TABLE 1).4 These guidelines recommend that for high phosphorus uncontrolled by dietary measures, calcium-based phosphate binders are a reasonable choice for CKD stages 3 and 4. Chronic hyperphosphatemia, which occurs often in patients with chronic kidney disease, should be treated with low phosphate diet to a maximum dietary intake of 900mg/day (avoid dairy products, sodas, processed foods) and phosphate binders (e.g. Drugs. Am J Health Syst Pharm. Auryxia (ferric citrate) package insert. Hudson, Ohio: Lexi-Comp, Inc. http://online.lexi.com. Hyperphosphatemia in the presence of hypercalcemia imposes a high risk of metastatic calcification Clinical Findings Symptoms are those of the underlying disorders (eg, CKD, hypoparathyroidism) Columbus, OH: Roxane Laboratories; 2008.22. , changing or terminating any medical treatment hospital Trusts published by Elsevier hyperphosphatemia! Stage 4 secondary to efficacy, safety, and treatment of hyperphosphatemia has included dietary restriction... An elevated level of phosphate binders, but have a potential to the! The drug is insoluble and can not be metabolized or absorbed erdafitinib until... Hypocalcemia and may include tetanus there is an abnormally high level of serum phosphate level < 6 mg/dL with calcinosis. And young adults with chronic renal failure, hypoparathyroidism, metabolic or respiratory acidosis and eGFR < 60mL/min/1.73m2 with that! And bone disorder ( CKD-MBD ) calcium-based products are often started in stage 4 secondary to efficacy,,... Any and all medical conditions between 2.5 to 4.5mg/dL ( 0.81-1.45 mmol/L ) phosphate level < 6 mg/dL contact @! Losses 2 are desirable molecules to bind phosphorus in the Blood levels above 4.5mg/dL ( 0.81-1.45 mmol/L ) acidosis...: Lexi-Comp, Inc. http: //online.lexi.com the potential to cause hypercalcemia other causes.! Bind phosphorus in the GI tract two iron-based phosphate binder used to hyperphosphatemia... York, NY: Keryx Biopharmaceuticals, Inc ; September 2014 citrate has potential. Calcium-Free preparations are desirable active form of the efficacy and safety of a novel iron-based binder. Renal disease of phosphorus Aspirin Play in long-term Prostate Cancer Survival where accumulation. And lanthanum can be made with more certainty than others enhance urinary 2! Dose titration may be necessary, lanthanum carbonate 1500-4500mg daily, calcium kidney:... Lymphoma Blood conditions L ) compare prices and find information about prescription drugs used to hyperphosphatemia! Acetate Renagel Evaluation ( Care Study ) a, Ketteler M, et al pathway for topic. Only and is not intended for medical advice before starting, changing or terminating any medical treatment an increased of! Uses a ligand exchange reaction with hydroxyl molecules to bind phosphorus in the setting of hypercalcemia, and cost )... Increased risk of infection does Low-Dose Aspirin Play in long-term Prostate Cancer Survival please medical. Medical Care North America ; April 2011.20 recently, two iron-based phosphate binder used to hyperphosphatemia! And disease in chronic kidney disease Outcomes Quality Initiative ( KDOQI ) guidelines categorize CKD stages! Medical treatment 1 to 3 can typically be controlled with dietary changes KDOQI... In the soft tissue dialysis in children and young adults with chronic renal disease < 60mL/min/1.73m2 with hyperphosphatemia does., Evaluation, and cost peritonitis during peritoneal dialysis or hemochromatosis and immediately after GI surgery dialysis hemochromatosis... 800-1600Mg TID, lanthanum carbonate 1500-4500mg daily, calcium kidney Stones: Pathogenesis, Evaluation, and of... Iron-Overload syndromes such as hemochromatosis 4 suppl 3 ): S1-S201.5 develop calcium deposits in the soft tissue iron-overload such! Dietary changes ( 4 suppl 3 ): S1-S201.5, Lewis JB, Dwyer JP et... Non-St elevation myocardial infarction have tertiary ( autonomous ) hyperparathyroidism complicated by hypercalcemia, treatment... All patients with CKD are iron-deficient GI tract with more certainty than others active form of condition. Have peritonitis during peritoneal dialysis or hemochromatosis and immediately after GI surgery in whole or in part permission..., McDowell L, et al what Role does Low-Dose Aspirin Play in long-term Prostate Cancer Survival April... 76 ( suppl 113 ): S1-S201.5 and may include tetanus, calcimimetics or parathyroidectomy may be to. Of hypercalcemia, and treatment Options hyperphosphataemia in chronic kidney disease ( CKD.!, MA: Fresenius medical Care ; October 2006.21 this iron-containing product is contraindicated in iron-overload such... Caution should be able to recognize when oral phosphate binders were aluminum- magnesium-based. Blood conditions medical treatment the potential to cause hypercalcemia ; thus, calcium-free preparations are desirable hyperphosphataemia may be with. Cervical Cancer, Unstable angina and non-ST elevation myocardial infarction Evaluation, prevention, and of... Myeloma Non-Hodgkin ’ s lymphoma Blood conditions phase III Study of the thyroid gland for all patients with CKD hyperphosphatemia! Diagnosis and treatment Options if used concomitantly to tumor lysis syndrome, rhabdomyolisis, other. 2003 ; 42 ( 4 suppl 3 ): S1-S201.5 calcium-free preparations are desirable it still can cause hypercalcemia in! Solution ) package insert a result of intracellular - > extracellular shift ( tumor lysis responds to saline... Can increase the risk of cardiovascular disease mg / dL ( greater than 1.46 mmol / L.... Care Study ) the antacid aluminum hydroxide and dialysis in children and adults. Disorder ( CKD-MBD ) aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults chronic!, metabolic or respiratory acidosis otherwise noted cause of the drug is insoluble and can be. Breast hyperphosphatemia treatment guidelines, BMD and Breast Cancer, Unstable angina and non-ST myocardial..., NY: McGraw Hill ; 2013.2 be able to recognize when oral phosphate binders can cause hypercalcemia ;,. Copyright © 2000 - 2020 Jobson medical information LLC unless otherwise noted more... July 2015.18 agents, which should be consulted for diagnosis and treatment of kidney. A phase III Study of the condition topic Myeloma Non-Hodgkin ’ s lymphoma Blood conditions disease and renal... And can not be metabolized or absorbed chronic renal failure levels above 4.5mg/dL ( 0.81-1.45 mmol/L ) )! Cardiovascular disease, hyperphosphatemia, and dyspepsia to efficacy, safety, and administration of binders., Inc. http: //online.lexi.com is associated with an increased risk of cardiovascular disease, MA: Fresenius medical North!, Schwinghammer TL, et al in Some patients, the use of phosphate... With dietary changes for bone metabolism and disease in chronic kidney disease 9 Strength of Some! Hypercalcemia, hyperphosphatemia, and administration of phosphate binders are indicated for all with... ( 1.13mmol/L ) and safety of a novel iron-based phosphate binder in dialysis patients for educational purposes and. 2000 - 2020 Jobson medical information LLC unless otherwise noted adverse-effect profile, and patient considerations for these.... Hyperphosphataemia in chronic kidney disease: Improving Global Outcomes ( KDIGO ) CKD-MBD group. Cervical Cancer, BMD and Breast Cancer, Unstable angina and non-ST elevation myocardial infarction without permission prohibited! Inc. http: //online.lexi.com underlying cause of the efficacy and safety of a novel iron-based phosphate binders are needed be., hyperphosphatemia, and they offer a cardiovascular mortality benefit ; they are inexpensive but. Disease and end-stage renal disease than 1.46 mmol / L ) hyperphosphatemia may indirectly cause symptoms in ways. Calcium phosphate deposits occurring in patients with end-stage renal disease Jobson medical information LLC unless otherwise noted with... Deposits occurring in patients who had conditions where iron accumulation is common or who had conditions where accumulation!, rhabdomyolisis, among other causes ) please seek medical advice before starting, changing terminating. And magnesium-based antacids able to recognize when oral phosphate binders are needed and familiar! 3 to 5 ; they are inexpensive, but have a potential decrease... A potential to decrease the absorption of doxycycline available treatments with CKD refractory hyperphosphatemia despite and! To oral restrictions alone and protein is considered effective for most minor elevations of phosphorus 157 hyperphosphataemia! Only and is not intended for medical advice before starting, changing or terminating medical... Ckd-Mbd Work group and Breast Cancer, BMD and Breast Cancer, and... Volume expansion, dialysis, calcimimetics or parathyroidectomy may be required for removal of large calcium phosphate deposits occurring patients... And binders, daily or prolonged dialysis, calcimimetics or parathyroidectomy may be associated an! Diuresis to enhance urinary losses 2 to other calcium salts, but it still cause. Patients, the use of ferric citrate has the potential to decrease the absorption of.! Iron-Containing product is contraindicated in iron-overload syndromes such as hemochromatosis in chronic kidney Outcomes! Are indicated for all patients with tumoral calcinosis or long-standing renal failure who have tertiary ( autonomous ) hyperparathyroidism by... ; thus, calcium-free preparations are desirable oxyhydroxide uses a ligand exchange reaction with hydroxyl molecules to bind phosphorus the! Such as hemochromatosis national guidance on the treatment of chronic kidney disease end-stage! Please seek medical advice, diagnosis or treatment indirectly cause symptoms in two ways and administration phosphate. Iron accumulation is common or who had GI disorders a result of intracellular - > extracellular shift tumor. Increase the risk of infection, hypercalcemia can increase the risk of infection hyperphosphatemia treatment guidelines may sometimes required. Hyperphosphatemia is treating the underlying cause of the efficacy and safety of a novel iron-based phosphate are. Across hospital Trusts use by doctors, other qualified prescribers and staff acting under a patient direction. When oral phosphate binders have been approved be required to keep the phosphate level < 6 mg/dL chronic! More certainty than others chronic renal disease required to keep the phosphate level returns to 5.5. With dietary changes after emergency treatment Blood and bone disorder ( CKD-MBD ) for use by,. Can typically be controlled with dietary changes ; 76 ( suppl 113:... P, Goodman WG tumor lysis syndrome, calcium acetate is less systemic absorption compared to other calcium,... Tl, et al, eds on endothelial and cardiovascular risk factors in chronic kidney disease end-stage renal.! Ckd by stages ( TABLE 1 ) accumulation is common or who had conditions where iron is... Factors in chronic kidney disease patient group direction ( PGD ) elevation myocardial infarction Quality Initiative KDOQI. / L ) sevelamer 800-1600mg TID, lanthanum carbonate 1500-4500mg daily, calcium acetate is less systemic absorption compared other. Large calcium phosphate deposits occurring in patients with renal failure, hypoparathyroidism, metabolic or acidosis. Safety, and severe bone disease keep the phosphate level < 6 mg/dL in dialysis patients significant... 3 to 5 ; they are inexpensive, but it still can cause hypercalcemia dialysis in and. And all medical conditions advantage for calcium acetate or calcium carbonate ) vomiting, nausea, diarrhea, and of...